Skip to main content
    N

    Nephros Inc (NEPH)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $3.00
    -0.05 (-1.64%)

    Market Cap: $33.15M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Nephros Inc (NEPH) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Nephros (NEPH) trades at 23.1x trailing earnings and 1.5x sales. Its P/S of 1.5x is below its 5-year median of 1.7x.

    Current Multiples

    Its enterprise value is 15.2x its EBITDA.

    MultipleValue
    P/E (trailing)23.1x
    Forward P/EN/A
    Price to sales1.5x
    Price to book2.6x
    EV/EBITDA15.2x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 46.4% below 2.8x and its P/B is 50.9% below 5.3x.

    MultipleCurrent5-year median10-year median
    P/S1.5x1.7x2.8x
    P/B2.6x2.8x5.3x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 102 to 119 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.1x in 2024 to 115.8x in 2019.

    Year endPriceP/EP/SP/B
    2025$4.8844.4x2.8x5.2x
    2024$1.47N/A1.1x1.8x
    2023$3.46N/A2.5x4.4x
    2022$1.16N/A1.2x2.1x
    2021$5.90N/A5.7x5.1x
    2020$8.58N/A8.9x6.2x
    2019$9.95N/A115.8x18.3x
    2018$5.13N/AN/A9.6x
    2017$4.05N/A22.1x827.5x
    2016$3.30N/A7.7x27.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NEPH

    Is NEPH stock overvalued?

    GNG's valuation label for NEPH is Undervalued.

    What is NEPH's price to sales ratio?

    Nephros has a price to sales ratio of 1.5x.